Efficacy of Cetuximab Combined with Chemotherapeutics versus Chemotherapeutics alone in the Treatment of Metastatic Colorectal Cancer:A Meta-analysis / 中国药房

ABSTRACT

OBJECTIVE:To systematically review the efficacy of cetuximab combined with chemotherapeutics versus chemo-therapeutics alone in the treatment of metastatic colorectal cancer,and provide evidenced-based reference for clinical treatment. METHODS:Retrieved from Medline,PubMed,EMBase,CJFD,VIP,WanFang database and Cochrane Library,randomized con-trolled trials(RCT)about the efficacy of cetuximab combined with chemotherapeutics(test group)versus chemotherapeutics alone (control group) in the treatment of colorectal cancer were collected. Meta-analysis was performed by using Rev Man 5.2 software after data extract and quality assessment. RESULTS:A total of 12 RCTs were included,involving 8 514 patients. Results of Me-ta-analysis showed progression free survival in test group was significantly longer than control group,the difference was statistical-ly significant [HR=0.87,95%CI(0.79,0.95),P=0.002];compared with control group,there were no significant differences in the disease control rate[OR=1.06,95%CI(0.88,1.27),P=0.54] and overall survival[HR=0.92,95%CI(0.85,1.00),P=0.05] in test group. Results of subgroup analysis showed cetuximeb could significantly prolong the progression free survival of KRAS wild-type patients,the difference was statistically significant[HR=0.80,95%CI(0.66,0.98),P=0.03]. CONCLUSIONS:Compared with che-motherapeutics alone,chemotherapeutics combined with cetuximab can significantly prolong the progression free survival of pa-tients with metastatic colorectal cancer. Due to the limits of quality and sample size,more strict designed,long-term follow-up of large scale RCTs are needed for the further verification of the conclusion.